IRCT20221101056360N1 IRCT 2023-01-30 Bagheiat-allah University of Medical Sciences Study of the efficiency of a novel desensitization protocol based on platelet infusion for decreasing anti-HLA antibody titer and increasing transplant ability Study of the efficiency of a novel desensitization protocol based on platelet infusion for decreasing anti-HLA antibody titer and increasing transplant ability 2022-05-20 anticipated 45 Complete https://irct.ir/trial/66728 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. N/A Novel desensitization protocol based on platelet, Anti-HLA antibody ,Kidney transplant, Desensitization. Intervention group: In this group of patients ,the following interventions are made .Each patient prophylaxis regimen includes cotrimoxazole 480 OD, pantoprazole 40 OD, vancomycin 500 after each platelet infusion. The immunosuppressive drugs that are used include PROGRAF 1 mg BD, prednisolone 10 mg OD. we give a single dose of Rituximab 500 mg on the first day of desensitization . After 3 days, 1: Platelet loading dose: 10 units of random platelets or two bags of single donor platelets, which continues for two days. 2: After the second day, platelets infusion continues (3 to 5 units of random platelets every other day) 3:BORTEZOMIB with the dosage of 1.3mg/m2 will be started for the patient every other day for 4 days 4: After completing four doses of BORTEZOMIB, the next four doses are continued as one dose every 72 hours. Also, in addition to receiving the above drugs, the patient receives IVIG at a dose of 1-2 gr/kg for three to five days. After two months, LUMINEX class one and two will be rechecked and immunosuppressive drugs are continued until the transplantation.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information